Tariff-related Litigation Update – 8/15
IEEPA Tariffs & Legal Challenge Update (8/15/2025)
This members-only briefing provides weekly updates on tariff actions and related litigation. It includes developments under Executive Order 14257 (as amended), recent tariff threats—including proposed “fentanyl” tariffs under IEEPA—and ongoing judicial activity in key trade and customs cases. Each update summarizes the latest filings, decisions, or scheduling milestones in active challenges brought by industry stakeholders.
Related Reading
News / China / Global & Trade / Supply Chain / Tariffs
AdvaMed Calls U.S.-China Trade Announcement a “Positive Step” for U.S.-led Medtech
November 3, 2025
WASHINGTON—AdvaMed, the medtech association, called the U.S.-China trade announcement a positive step toward supporting the U.S.-led medtech industry and its service to patients nationwide and globally.
Resource / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
AdvaMed® Advancements: Q3 2025 Report
October 31, 2025
AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment, AdvaMed remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to advancing breakthrough coverage legislation. Learn more
Resource / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs / Workforce Advancement
The Economic Impact of the Medical Technology Industry 2024
October 27, 2025
Explore AdvaMed’s 2024 Economic Impact Report, developed by Frost & Sullivan, highlighting medtech’s vital contributions to the U.S. economy
News / Global & Trade / Supply Chain / Tariffs
AdvaMed Responds to Commerce Department Section 232 National Security Investigation, Seeks Policies to Strengthen U.S. Position as Global Medtech Leader
October 17, 2025
WASHINGTON—AdvaMed, the medtech association, today submitted formal comments responding to the U.S. Department of Commerce investigation into whether the U.S.’s current level of medtech imports has national security implications. The comments outlined medtech as an American success story and the United States as the global leader in innovating and making the highest quality medtech for the United States and world, an export powerhouse, and much less reliant on medtech imports than sometimes perceived.
News / Global & Trade / Government & Legislative Affairs / Health Access / Supply Chain / Tariffs
AdvaMed Statement on Commerce Department Section 232 National Security Investigation
September 25, 2025
WASHINGTON—AdvaMed, the MedTech Association, released the following statement from President and CEO Scott Whitaker on the Administration’s announcement of its investigation under Section 232 of the Trade Expansion Act into whether the U.S.’s current level of medtech imports has national security implications:
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 9/12
September 12, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 9/5
September 5, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 8/22
August 22, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.